Kornimate/medical-research-clean huggingface dataset:
the assessment of the prevalence, clinical course and treatment of covid-19 complications

Conditions: COVID-19; Coronavirus Infection; Sars-CoV2; Complications

Summary: sar-cov-2 infection and its clinical manifestation known as covid-19 beside the respiratory and lung involvement may include the cardiovascular system, the nervous system and the liver. in the acute phase of the disease, all of these conditions may be life-threatened. as a result, after the acute phase of covid-19, early complications may be observed, including heart, lungs, brain, muscles and liver. a few papers to date have been reported of myocarditis, ventricular arrhythmias, post-inflammatory changes in the lung and liver, as well as ischemic changes in the brain, diseases of skeletal muscle, which may have adverse prognostic effects. due to the extent of the pandemic, the severity of the complications and the expected high complications' prevalence in the early post-recovery period, a study was designed to determine the extent of the problem of early complications after covid-19. complex cardiological, pulmonary, neurological and hepatological diagnostics are planned, including laboratory, imaging and functional tests. the results obtained, in addition to determining the scale of the problem, will allow the selection of studies that optimally identify patients with early complications. the purpose of this procedure is to enable rapid treatment of diseases that are complications of sars-cov-2 infection. an additional aspect raised in the project will be the issue of psychiatric disorders (anxiety, depression, post traumatic disorders). the main three purposes of the study include: 1. the assessment of prevalence of particular complications after covid-19. 2. identification of the demographic and clinical risk factors of covid-19 complications 3. determining the diagnostic tests which are sufficient to detect early complications of covid-19


Eligibility criteria:
inclusion criteria: 1. sars-cov-2 rna confirmed by the pcr method in the acute phase of disease. 2. presence of the clinical symptoms associated with covid-19 in the acute phase of disease 3. two negative results of sars-cov-2 pcr test following the 7-day period of quarantine 4. informed consent exclusion criteria: 1. any symptoms of infection during the quarantine 2. lack of patient's consent 3. lack of possibility of travelling to the hospital for tests

Keywords: covid-19 sars-cov2 complications
vitamin d supplementation for the prevention of acute respiratory infections: a rct in young finnish men

Conditions: Vitamin D Deficiency; Respiratory Tract Infections

Summary: vitamin d intervention effects on the prevention of acute respiratory tract infections among young finnish men


Eligibility criteria:
inclusion criteria; * male * 18-29 years of age * examined as healthy according to finnish military health care regulations exclusion criteria * female * age \> 30 yrs
a long-term study for the outcome of pompe disease

Conditions: Pompe Disease

Summary: prospectively follow patients with pompe disease underwent enzyme replacement therapy.


Eligibility criteria:
inclusion criteria: confirm diagnosis with pompe disease, is or is preparing receiving enzyme replacement therapy exclusion criteria: no
interest of bilateral basic tongue mucosectomy assisted by robot or laser in combination with tonsillectomy in the assessment of prevalent cervical lymphadenopathy

Conditions: Cancer of Head and Neck; Adenopathy

Summary: we are proposing a randomized phase ii study to assess the benefit of bilateral robot-assisted or laser basal tongue mucosectomy in combination with tonsillectomy in the assessment of prevalent cervical lymphadenopathy


Eligibility criteria:
inclusion criteria: * patient with a prevalent head and neck lymphadenopathy with positive or non-contributory fine needle aspiration, or having had an adenectomy revealing a metastasis of squamous cell carcinoma, a pet examination, an injected cervico-thoracic ct and an ent work-up (nasofibroscopy) not finding a primary tumor * performance status \< 2 * patient aged 18 or over * patient affiliated with social security system * informed consent signed exclusion criteria: * history of squamous cell carcinoma of the vads or skin of the face. * history of cervico-facial radiotherapy * primary tumor discovering during pan-endoscopy * inexposable patient lead not to possible mucosectomy * uncontrollable hemostasis disorders (contraindication to tonsillectomy and basic bilateral mucosectomy of language) * distant metastases * lymphadenopathy inoperable * patient with a contraindication to radiotherapy * pregnant or breastfeeding woman * women of childbearing potential without effective contraception * patient under guardianship or unable to give informed consent * patient unable to undergo the trial follow-up for geographic, social or psychopathological reasons

Keywords: mucosectomy tonsil
unraveling metabolic involvement in facioscapulohumeral dystrophy through metabolomics

Conditions: Facioscapulohumeral Muscular Dystrophy

Summary: the pathogenesis of facioscapulohumeral dystrophy (fshd), one of the most prevalent types of inherited muscle disease, is unknown. the reasons underlying its significant clinical heterogeneity, incomplete penetrance, and sex specific differences in the age of onset, are not currently understood. while metabolic changes associated with this disease have so far deserved little attention, recent studies have pinpointed significant metabolic dysregulation as an emerging driving mechanism in the pathophysiology of this untreatable disease. to test this hypothesis, we will perform a deep metabolic phenotyping in a large cohort of highly clinically characterized fshd patients at different stage of disease and age/sex-matched controls by state-of-art plasma metabolomic and mitochondrial biomarker profiling. these data will allow attributing specific metabolomic signatures to different stages of the disease in each sex. metabolic pathway analysis will allow gaining insights into the type of metabolic dysregulation associated with the disease pathogenesis, leading to the identification of targeted metabolic/nutritional interventions and biomarker discovery.


Eligibility criteria:
inclusion criteria: * participant fasting for at least 8 h at the time of blood sampling * patient with a molecular diagnosis of fshd (know number of d4z4 contractions) * patient with a typical fshd presentation (at least facial, pelvic ans scapular girdles signs) * patient with a preserved ability to ambulate at the time of the selection (use of a cane is allowed) exclusion criteria: * severe cardiac and respiratory dysfunction. * presence of severe systemic diseases unrelated to fshd. * presence of uncontrolled diabetes or hypothyroidism. * alcohol or toxic abuse.
casopitant (oral) and zofran to prevent postoperative nausea and vomiting in women

Conditions: Nausea and Vomiting, Postoperative

Summary: this study is being conducted to see if adding gw679769 (casopitant) to zofran will significantly decrease the number of patients who experience nausea and vomiting after surgery.


Eligibility criteria:
inclusion criteria: * history of ponv and/or motion sickness. * have not smoked for the last 6 months. * having certain types of abdominal, breast or shoulder surgeries. exclusion criteria: * pregnant or breastfeeding. * taking certain medications. * have certain pre-existing medical conditions.

Keywords: postoperative nausea and vomiting ponv antiemetics nk-1 5ht3 casopitant mesylate zofran ondansetron hydrochloride
davos alzheimer's collaborative study: sequential administration of digital testing to screen for cognitive impairment followed by blood based biomarkers to assist with timely detection and accurate diagnosis of alzheimer's disease

Conditions: Alzheimer Disease

Summary: the purpose of this study is to investigate how we can detect alzheimer's disease early by using an online memory test and a simple blood test. these new methods for early diagnosis could allow people to begin treatment sooner, with the potential to improve the lives of millions of people.


Eligibility criteria:
inclusion criteria subjects must meet the following criteria for entry into the study: 1. male or female \> 65 years of age at the time of consent; 2. understand and voluntarily sign an informed consent form; inclusion criteria is assessed at both e-consent (assessed by participant's self-reporting of age and understanding) and in-person consent at tri (assessed by clinical research coordinators in tri). exclusion criteria subjects who meet any of the following criteria will not be eligible for entry into the study: 1. subjects who are unable to hear and see well enough to complete the assessments; 2. prior diagnosis of dementia or alzheimer's disease documented in their medical record and/or as diagnosed by a physician; exclusion criteria is assessed by by participant's self-reporting of understanding and not having a prior diagnosis of dementia at the time of e-consentand visit 1 at tri. ).
oral iron supplementation in pulmonary hypertension

Conditions: Pulmonary Arterial Hypertension

Summary: the purpose of this study is to investigate the effects of iron supplementation in patients with pulmonary arterial hypertension and iron deficiency.

pulmonary arterial hypertension (pah) is a chronic disease associated with upregulation of hypoxia inducible-factor-1alpha (hif-1alpha) and functional iron deficiency. the investigators are proposing a prospective, single-arm, open-label intervention to determine whether oral iron supplementation in patients with pulmonary arterial hypertension reduces markers of hif activation and improve clinical parameters of disease. after the baseline visit, patients will be given ferrous sulfate tablets to take orally for 3 months. outcome data will be collected at the baseline visit and at the end of the 3-month study period.

Eligibility criteria:
inclusion criteria: * age 21 and older * diagnosis of idiopathic pulmonary arterial hypertension * iron deficiency (transferrin saturation \<20% and serum ferritin \< 100 ug/l) exclusion criteria: * active infection, malignancy, or bleeding * hemochromatosis * chronic inflammatory or autoimmune disease * currently taking experimental/study medications, erythropoietin, iron supplementation, or immunosuppressants * allergy to iron

Keywords: iron deficiency pulmonary hypertension iron supplements ferrous sulfate
serious game therapy in neglect patients

Conditions: Stroke; Unilateral Spatial Neglect

Summary: the growing field of new technologies offers new perspectives for neurorehabilitation. serious games are a promising solution in the rehabilitation of cognitive impairments, and they may be useful in the rehabilitation of unilateral spatial neglect. investigators developed a rehabilitation program for visual exploration training with a serious game and investigated its efficiency. twelve patients with unilateral spatial neglect after a right hemispheric stroke were recruited. six patients assigned to a group received both serious game training and conventional rehabilitation, and after only conventional rehabilitation; and six patients assigned to another group received first conventional rehabilitation and then serious game training and conventional rehabilitation. the investigators compared the two groups after rehabilitation.


Eligibility criteria:
inclusion criteria: * unilateral spatial neglect syndrome * right cerebral lesion exclusion criteria: * epilepsia * general mental deterioration * psychiatric disorder * no prior history of neurological disease

Keywords: rehabilitation new technology unilateral spatial neglect
chief-pd (cholinesterase inhibitor to prevent falls in parkinson's disease)

Conditions: Parkinson Disease

Summary: parkinson's disease is a common condition particularly affecting older people. falls are a very frequent complication of the disease affecting 60% of people with parkinson's every year. as the population ages, the number of people living with parkinson's disease and the occurrence of complications will increase. the loss of the chemical dopamine in the brain causes walking in parkinson's to become slower, unsteady and irregular. people with the condition are therefore at a very high risk of falling. to some extent, people can compensate for these changes by paying more attention to their walking. however, parkinson's also diminishes memory and thinking ability. this decreases people's ability to pay attention to their walking, especially when doing something at the same time. cholinesterase inhibitor (cheis) are drugs that are currently used to treat people with memory problems in parkinson's. the effect of these drugs on falls in parkinson's has been tested to show that treatment has the potential to almost halve the number of falls. this trial aims to definitively determine whether cholinesterase inhibitors (chei), can prevent falls in parkinson's and whether this treatment is cost effective. 600 participants with parkinson's disease will be enrolled from hospitals throughout the uk. participants will be randomly assigned to either receive the drug (chei) via a patch or receive a placebo (dummy) treatment via a patch. neither the researchers nor the participants will know which group they are in. participants will take the medication for 12 months and record any falls that they experience in diaries. if successful, this treatment in parkinson's disease, would tackle one of the most disabling complications of the disease and positive findings will provide robust evidence to change clinical practice.


Eligibility criteria:
inclusion criteria: * diagnosis of idiopathic parkinson's disease. * modified hoehn and yahr stage 1-4 disease as determined at baseline visit. * have experienced a fall in the previous year. * able to walk ≥10m without aids or assistance. * 18+ years of age. exclusion criteria: * previous chei use in 12 months prior to enrolment. * hypersensitivity to rivastigmine * dementia diagnosed according to mds criteria (6). * inability to attend or comply with treatment or follow-up scheduling. * non-english-speaking patients (cognitive tests performed in english). * falling ≥4x per day. * unwillingness to use an acceptable method of contraception for the duration of the trial if they are of childbearing potential. * pregnancy and/or breastfeeding

Keywords: parkinson disease parkinson rivastigmine falls cholinesterase inhibitors phase iii
effectiveness of the tb contact priority model

Conditions: Tuberculosis

Summary: the broad purpose of this project, proposed by investigators at the university of alabama at birmingham and the state of alabama department of public health, is to use a behaviorally focused education that has been proven effective to enhance the accuracy and efficiency of the contact investigation process. the behaviorally focused intervention will focus on enabling public health workers to understand and implement a recently published model of tb transmission.

background: investigation of contacts of patients with active pulmonary tuberculosis (tb) is an important epidemiological tool in tb control. unfortunately, due to budgetary and resource constraints, many health departments struggle to fulfill their responsibility of tb control through contact investigation. design narrative: primary outcome the primary outcome of this project is to examine the clinical effectiveness of the tb transmission model. this will be done by examining the sensitivity and specificity of the model when used in a field application. key secondary outcomes evaluation of the efficiency of contact investigation (two outcomes: 1) weekly average time to tuberculin skin test placement for high risk contacts, 2) weekly average time to the close of the contact investigation.) qualitative assessment of individuals who are incorrectly predicted by the model to have a negative tuberculin skin test

Eligibility criteria:
b field workers for the alabama department of public health.
bioflow-sv all comers registry

Conditions: de Novo; Symptomatic Ischemic Heart Disease; Restenoses, Coronary

Summary: assessment of the clinical safety and performance of the orsiro drug-eluting stent in a real world setting in patients with small vessels with reference vessel diameter ≤2.75 mm.

prospective, single-arm, multi-center, all-comers registry with clinical follow-up visits at the hospital or by phone at 6 and 12 months post-procedure. a minimum of 1000 patients will be enrolled in approximately 15 sites in brazil, including at least 415 patients with reference vessel diameter ≤2.75 mm as assessed by online qca.

Eligibility criteria:
inclusion criteria: * subjects ≥18 years of age * subject must sign a patient informed consent (pic) * subject must agree to undergo all required follow-up visits, either at the hospital or by phone. * subject with coronary artery disease requiring treatment with orsiro sirolimus eluting stent system exclusion criteria: * pregnant and/or breast feeding females at the time of enrolment * known allergies to acetylsalicylic acid (asa), clopidogrel, ticlopidine, heparin or any other anticoagulant /antiplatelet required for pci, contrast medium, sirolimus, or similar drugs, or the stent materials that cannot be adequately pre-medicated * currently participating in another study that has not yet reached the primary endpoint.
clinical efficacy and safety of a subcutaneous immunotherapy with gpasit+™ in patients with grass pollen-induced allergic rhinoconjunctivitis

Conditions: Hay Fever

Summary: gpasit+tm product is based on highly purified allergen fragments obtained from grass pollen. the purpose of this study is to demonstrate the clinical efficacy and safety of a subcutaneous immunotherapy with gpasit+™ in patients with grass pollen-induced allergic rhinoconjunctivitis compared to placebo.


Eligibility criteria:
key inclusion criteria: * allergy diagnosis: * a medical history of moderate to severe seasonal allergic rhinoconjunctivitis (sarc) for the grass pollen season during at least the two previous seasons (definition of allergy severity according to aria (bousquet et al 2001)) * a positive skin prick test (spt - wheal diameter ≥ 3 mm) to grass pollen mixture, histamine wheal ≥ 3 mm, nacl control reaction \< 2 mm * specific ige against grass pollen (with recombinant allergens - g213) \> 0.7 ku/l * positive response to cpt with at least 10,000 sq-e/ml of grass allergens * patients treated with anti-allergic medication for at least 2 grass pollen seasons prior to enrollment * for asthmatic patients: confirmed diagnosis of controlled asthma according to global initiative for asthma (gina) guidelines (steps 1-3, gina 2014) key exclusion criteria: * previous immunotherapy with grass allergens within the last 5 years * ongoing immunotherapy with grass allergens or any other allergens * patients with a history of anaphylaxis, including food (e.g. peanut or marine animals) or hymenoptera venom (e.g. bee or wasp stings) or medication (e.g. penicillin) * patients with partly controlled or uncontrolled asthma according to gina guidelines (gina 2014) * patients with chronic asthma or emphysema, particularly with a forced expiratory volume in 1 second (fev1) \< 80% of the predicted value (ecsc) or with a peak expiratory flow (pef) \< 70% of the individual optimum value * patients symptomatic to inhaled allergens circulating during the grass pollen season (specific to each country: e.g. birch, hazel, mugwort, ragweed, olive, alternaria alternata) * patients symptomatic to perennial inhaled allergens (house dust mites, cat, dog) to which the patients are regularly exposed
tdcs effect on psychotic symptoms in dementia with lewy bodies (dlb), and impacts on caregiver burden

Conditions: Lewy Body Dementia; Lewy Body Dementia With Behavioral Disturbance; Burden, Caregiver; Lewy Body Disease; Dementia With Lewy Bodies

Summary: the goal of this pilot prospective study is to evaluate the effect of tdcs on psychotic-like symptoms in patients with lewy body dementia (lbd). the main questions it aims to answer are: * what is the effect of tdcs on neuropsychiatric symptoms, especially psychotic-like symptoms? * what is the impact of tdcs on caregiver burden? researchers will compare active tdcs (2ma stimulation, anode on the left dorsolateral prefrontal cortex, cathode on the right fronto-orbital) to sham tdcs (placebo stimulation, no intensity applied) to see if there is an effect on reducing psychotic-like symptoms and on caregiver burden. participants will: * undergo a stimulation phase consisting of 10 tdcs sessions of 20 minutes each, spread over 2 consecutive weeks (5 days with stimulation, 2 days without stimulation, 5 days with stimulation). * perform assessments at t0 (inclusion), t1 (at the end of the stimulation phase), and t2 (follow-up at 8 weeks post stimulation).


Eligibility criteria:
inclusion criteria: * male or female, aged over 60, * diagnosed with a neurodegenerative pathology of the dlb type, at a moderate stage, according to the mckeith and al. (2017) criteria * no change in antiparkinsonian or psychotropic medications, or cholinesterase inhibitors, for a period of one month prior to inclusion, * mini mental state examination (mmse) \> 15, * composite score called "psychotic factor" (corresponding to the sum of the psychotic-type symptoms sub-scores from the npi \[12\]) greater than 0, * presence of a family caregiver, * sufficient written and oral expression in french, * written informed consent signed by the patient and his/her family caregiver exclusion criteria: * history of alcoholism, drug addiction or neurological diseases such as brain trauma, epilepsy, encephalitis, intracranial normal-pressure hydrocephalus, etc. which may lead to cognitive impairment, * concomitant major psychiatric illness, * significant physical illness or comorbidities * history of moderate to severe visual impairment secondary to glaucoma, cataract or macular degeneration, * patient under guardianship or curators

Keywords: transcranial direct-current stimulation (t-dcs) brain stimulation psychotic symptoms caregiver burden
thrombolysis in stroke with unknown onset based on noncontrast ct

Conditions: Stroke, Acute

Summary: multicentric, observational, registry-based study of 0.9 mg/kg i.v. thrombolysis in wake-up stroke or stroke with unknown onset based on non-contrast ct appearance only

thrombolysis in wake-up stroke (wus) or stroke with unknown onset (suo) has been recently proven to be safe and effective using magnetic resonance imaging (mri). however, in most of the thrombolyzing hospitals worldwide mr imaging is not available. we hypothesize that pragmatic non-contrast ct (ncct)-based wus/suo thrombolysis may be feasible and safe. methods: trust-ct is an international multicenter registry-based study. wus/suo patients undergoing ncct-based thrombolysis with nihss ≥ 4 and initial aspects ≥ 7 are included and compared to propensity score matched non-thrombolyzed wus/suo controls. primary endpoint is symptomatic intracranial hemorrhage (ich); secondary endpoints include 24-hour nihss change of ≥ 4 and modified rankin score (mrs) at 90 days.

Eligibility criteria:
inclusion: 1. ischemic stroke with nihss ≥ 4 2. wake-up stroke or unknown onset stroke 3. age ≥ 18 years 4. rtpa bolus within 4.5h of awakening and/or within 4.5 of discovering symptoms 5. rtpa bolus within 30 min. of admission ct exclusion: 1. noncontrast cranial ct scan with aspects \< 7 2. evidence of intracranial or subarachnoid hemorrhage 3. inability to control systolic bp \>185mm hg, or diastolic bp \>110mm hg with iv antihypertensive medication 4. known coagulopathy or evidence of active bleeding 5. surgical procedures, subclavian arterial puncture, trauma, and gastrointestinal or genitourinary bleeding within 14 days of the event 6. patients taking oral anticoagulants and having an inr \>1.7 7. a platelet count \ 450 8. premorbid mrs \> 3